EPO Revokes Controversial Patent For Breast Cancer Screening

Law360, New York (May 19, 2004, 12:00 AM EDT) -- The European Patent Office has revoked U.S. biotechnology company Myriad Genetics’ European patent on a controversial breast cancer genetic test that critics claim is excessively expensive.

The patent covers a test to predict if a woman is at high risk of developing breast cancer by looking for mutations in a gene called BRCA1.

“After a public hearing of all parties to the opposition proceedings against the patent, the division - a panel composed of three patent examiners and a legal expert - concluded that the grounds...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.